Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
09/18/2018 09/19/2018 09/20/2018 09/21/2018 09/24/2018 Date
74.9(c) 75.12(c) 74.67(c) 74.5(c) 74.29 Last
2 037 721 1 768 791 2 747 102 7 333 184 49 517 Volume
-0.27% +0.29% -0.60% -0.23% -0.28% Change
More quotes
Financials (EUR)
Sales 2018 35 107 M
EBIT 2018 8 381 M
Net income 2018 5 005 M
Debt 2018 16 227 M
Yield 2018 4,13%
Sales 2019 36 057 M
EBIT 2019 8 786 M
Net income 2019 5 356 M
Debt 2019 15 275 M
Yield 2019 4,24%
P/E ratio 2018 18,08
P/E ratio 2019 16,81
EV / Sales2018 3,12x
EV / Sales2019 3,01x
Capitalization 93 247 M
More Financials
Company
Sanofi engages in the research, production and distribution of pharmaceutical products.It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Human Vaccines.The Pharmaceuticals segment comprises the commercial operations of the following global franchises:... 
Sector
Pharmaceuticals
Calendar
10/31 | 02:30pmEarnings Call
More about the company
Surperformance© ratings of Sanofi
Trading Rating : Investor Rating :
More Ratings
Latest news on SANOFI
09/22SANOFI : Catholic Church partner on diabetes, hypertension management
AQ
09/20STUDIES FROM SANOFI UPDATE CURRENT D : is...
AQ
09/20SANOFI : New Zika Virus Findings from Sanofi Pasteur Discussed
AQ
09/20SANOFI : Findings on FDA Actions Detailed by Investigators at Genzyme Corporatio..
AQ
09/20SANOFI : Recent Research from Sanofi Pasteur Highlight Findings in Vaccines (Al-..
AQ
09/20SANOFI : Coughs Up $25 Million to Settle SEC FCPA Charges
AQ
09/20SANOFI : Coughs Up $25 Million to Settle SEC FCPA Charges
AQ
09/20SANOFI : Catholic Partner to Address Diabetes, Hypertension in Nigeria
AQ
09/19SANOFI : Galera raises $150 million, will hire staff for cancer-radiation side-e..
AQ
09/18SANOFI : unveils eczema drug data, as regulators mull label expansion
AQ
More news
Sector news : Pharmaceuticals - NEC
08:30aASTRAZENECA : Mixed Results from Farxiga Trial
DJ
08:16aSHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
03:05aAs China builds biotech sector, cash floods U.S. startups
RE
09/23ASTRAZENECA CEO WARNS OF MEDICINE SH : Sunday Times
RE
09/22J&J UNIT : Esketamine Study Didn't Show Statistical Significance for Primary End..
DJ
More sector news : Pharmaceuticals - NEC
MarketScreener Strategies on SANOFI 
SANOFI - 05/15
Attractive price levels
BUY
SANOFI - 2017
Good timing to go long again
BUY
More Strategies
Latest Tweets
09/23Federal prosecutors are probing whether big drugmakers including Sanofi, Gile..
19
09/22$0.93 EPS Expected for Sanofi SA $SNY This Quarter
1
09/22Bayer’s pharma unit head Weinand quits to join Sanofi  
09/21$GILD $SNY $BIIB Feds Probing Drugmakers Including Sanofi, Gilead, and Biogen..
2
09/20eyeforpharma spoke to Lisa Egbuonu-Davis, VP, Global Patient Centered Outcome.. 
More tweets
Qtime:1026
News from SeekingAlpha
09/23BeiGene's zanubrutinib shows encouraging action in early-stage lymphoma study 
09/21Feds looking into free services from drug makers - WSJ 
09/20Arvinas Holding Prepares Terms For $100 Million IPO 
09/15Regeneron and Sanofi's Dupixent shows treatment benefit in adolescents with a.. 
09/15STOCKS TO WATCH : Oracle Looks To Lift Tech Sector 
STOCK PICK
At a crossroads
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 80,2 €
Spread / Average Target 7,7%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & Executive VP-Finance
Ameet Nathwani Executive Vice President-Medical Affairs
John C. Reed Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI3.69%109 540
JOHNSON & JOHNSON2.26%383 312
PFIZER21.65%258 285
NOVARTIS-0.63%216 108
ROCHE HOLDING LTD.-4.60%211 501
MERCK AND COMPANY26.36%189 092